4-MeO-PCP

4-Methoxyphencyclidine

Methoxydine, 4-Methoxy-PCP

Psychoactive Class

Chemical Class

4-MeO-PCP is an arylcyclohexylamine synthetic dissociative that can produce hallucinogenic and anesthetic effects. First synthesized in 1965 by Parke-Davis chemist Victor Maddox, it became the first arylcyclohexylamine research chemical sold online when it appeared in late 2008. It is reported to have reduced potency relative to PCP. Dosage information remains tentative, potentially due to variations in the potency of available supplies.

Dosage & Duration

Dosage

Threshold~25 mg

Light25-75 mg

Moderate75-150 mg

Strong150-250 mg

Heavy250+ mg

Dosage information for 4-MeO-PCP remains poorly characterized, and some user reports may involve misidentified substances. Sensitivity varies considerably between individuals, and dose-response relationships appear inconsistent.

Duration

Onset45-120 minutes

Come Up60-120 minutes

Peak3-7 hours

Offset6-10 hours

After Effects6-12 hours

Total12-20 hours

Subjective Effects

Effects vary widely by individual, dose, and context.

Forked from Subjective Effect Documentation work

by Josie KinsAugust 2016.

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

4-MeO-PCP acts primarily as an NMDA receptor antagonist.¹ Its NMDA affinity is lower than that of PCP but higher than that of ketamine. The compound also binds with notable affinity to σ1 and σ2 receptors, and shows moderate affinity for the norepinephrine and serotonin transporters.¹ It is considered a relatively selective NMDA receptor ligand, lacking appreciable affinity for the dopamine transporter.¹

Pharmacokinetics

4-MeO-PCP is orally active, indicating sufficient oral bioavailability for pharmacological effects. No detailed data on its metabolic pathways, metabolizing enzymes, or elimination half-life have been reported.

Metabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

DepressantsStimulants

TripSit

Tolerance

Full Tolerance

With sustained repeated use, many effects may weaken, requiring higher doses for comparable results.

Baseline Reset

1-2 weeks

Half Tolerance

3-7 days

Cross Tolerance

Dissociatives

Harm Potential

Addiction & Dependence

Psychological

Moderate

Chronic use can be moderately addictive with high potential for abuse and is capable of causing psychological dependence among certain users. Cravings may occur if usage is suddenly stopped.

Physical

Low

Withdrawal effects have been reported upon cessation of chronic use, though specific physical withdrawal symptoms are not well characterized due to limited research history.

Toxicity

Urinary System

Repeated excessive use over extended periods may cause bladder and urinary tract problems similar to those seen with ketamine, including urinary frequency and urgency, pelvic and bladder pain, hematuria, and incontinence; these effects can be avoided by limiting use to less than weekly.

Psychosis Risk

Psychotic episodes, disturbing hallucinations, delusions, anxiety, and paranoia are reported as potential negative effects. Risk of adverse psychological reactions increases with higher doses and redosing.

History & Culture

4-MeO-PCP was originally synthesized in 1965 by Victor Maddox, a medicinal chemist working at the pharmaceutical company Parke-Davis. The compound remained largely obscure for decades following its initial creation.…

Legality

By Country

United StatesUnscheduled (Federal Analogue Act may apply)

Not federally scheduled, but may be prosecuted as a PCP analogue under the Federal Analogue Act when sold for human consumption or possessed with intent to ingest. The DEA has indicated it considers structurally similar recreational drugs to be controlled substance analogues. Virginia temporarily classified it as Schedule I from June 26, 2019 through December 25, 2020.

GermanyControlled (NpSG)

Controlled substance under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since September 27, 2021. Production, distribution, and possession with intent to supply are prohibited.

SwitzerlandControlled (Verzeichnis E)

Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.

United KingdomClass B

Controlled under the Misuse of Drugs Act 1971. Covered by the arylcyclohexylamine generic clause added by S.I. 2013/239, which came into effect on February 26, 2013.⁴ This clause encompasses derivatives of 1-phenylcyclohexylamine where the amine has been replaced with a piperidyl group and further substituted in the phenyl ring with an alkoxy substituent.⁴ Possession, production, supply, and importation are prohibited.

ChileIllegal

Prohibited under Ley 20000 (the Chilean drug control law), which explicitly covers all esters and ethers of phencyclidine.³ As 4-MeO-PCP is an ether of PCP, it falls under this provision.

SwedenProposed hazardous substance

Sweden's public health agency recommended classifying 4-MeO-PCP as a hazardous substance on November 10, 2014.

TurkeyIllegal

Classified as a controlled drug under national legislation. Possession, production, supply, and importation are prohibited.

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 4-MeO-PCP article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

4-MeO-PCP

4-Methoxyphencyclidine

Methoxydine, 4-Methoxy-PCP

Psychoactive Class

Dissociative Hallucinogen

Chemical Class

Arylcyclohexylamine